NexMed presents Phase II Alprox data

NEXM said that in a U.S. Phase II trial of its Alprox-TD cream to treat erectile dysfunction, improvements in erectile function (EF) score of 1.9 and 4.5 (p=0.05 and p<0.001 respectively) were seen in...